Publications by authors named "S M Carrillo-Vazquez"
Article Synopsis
- The update of the Mexican Guidelines for the Treatment of Systemic Lupus Erythematosus has been developed with input from various experts across the country.
- The new guidelines follow the GRADE system, which helps in evaluating the quality of evidence for healthcare recommendations.
- Key new topics included in the update are vaccines, pregnancy, and cardiovascular risk, which were not addressed in the previous guidelines from 2017.
Objective: To develop updated guidelines for the pharmacological management of rheumatoid arthritis (RA).
Methods: A group of experts representative of different geographical regions and various medical services catering to the Mexican population with RA was formed. Questions based on Population, Intervention, Comparison, and Outcome (PICO) were developed, deemed clinically relevant.
Article Synopsis
- - The Mexican Academy of Dermatology (AMD) supports the use of certain biosimilars for psoriasis treatment, indicating that some, like adalimumab, infliximab, and etanercept, have comparable pharmacokinetics and pharmacodynamics.
- - However, the AMD states that there isn't enough evidence to recommend these biosimilars as interchangeable or to broaden their indications without careful consideration.
- - They emphasize the importance of strict pharmacovigilance to monitor adverse effects and ensure patient safety, stressing that economic benefits should not compromise scientific rigor in treatment effectiveness.
Background: This article presents evidence and recommendations regarding the efficacy and safety of the approved and available therapies in Mexico to treat severe or established osteoporosis with the aim of developing a position regarding therapeutics in this stage of the disease, according to the descriptive cards of the National Drug Formulary of the National General Health Council of Mexico.
Methods: We performed a systematic and narrative review of the evidence of teriparatide and denosumab, from their pharmacological profile, effectiveness, and safety derived from clinical trials, as well as an analysis of the general recommendations of the national and international clinical practice guidelines.
Results: The evidence establishes that teriparatide and denosumab belong to different therapeutic classes, with biologically opposed mechanisms of action and indications of use, which are clearly differentiated in their respective national codes, therefore these drugs cannot be substitutable or interchangeable in severe osteoporosis therapy.
The aim of this paper is to evaluate the relationship of salivary ammonium levels and the presence of bacteria with rheumatoid arthritis (RA) clinical disease activity in a cross-sectional study of Mexican patients. From a periodontal and disease activity standpoint, 132 consecutive RA patients fulfilling clinical criteria were evaluated. Ammonia levels (including peptidyl arginine deiminase activity) were evaluated by colorimetric assay and the presence of , , and was evaluated by polymerase chain reaction (PCR) technique.
View Article and Find Full Text PDF